Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Toni K ChoueiriThomas PowlesKatriina PeltolaGuillermo de VelascoMauricio BurottoCristina SuarezPooja GhataliaRoberto IacovelliElaine T LamElena VerzoniMahmut GümüşWalter M StadlerChristian KollmannsbergerBohuslav MelicharBalaji VenugopalMarine Gross-GoupilAlexandr PoprachMaria De SantisFabio A SchutzSe Hoon ParkDmitry A NosovCamillo PortaJae Lyun LeeXavier Garcia-Del-MuroElisa BiscaldiRay Manneh KoppMototsugu OyaLi HeAobo WangRodolfo F PeriniDonna VickeryLaurence AlbigesBrian Rininull null

Published in: The New England journal of medicine (2024)

Belzutifan showed a significant benefit over everolimus with respect to progression-free survival and objective response in participants with advanced clear-cell renal-cell carcinoma who had previously received immune checkpoint and antiangiogenic therapies. Belzutifan was associated with no new safety signals. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; LITESPARK-005 ClinicalTrials.gov number, NCT04195750.).

Keyphrases